Aim: To evaluate the association between echocardiographic right ventricular (RV) structural and functional parameters and galectin-3 levels in patients with chronic obstructive pulmonary disease (COPD) and associated pulmonary hypertension presenting with acutely aggravated dyspnoea. Material and methods: We conducted a prospective study on forty patients with COPD and forty healthy volunteers matched for age and sex (mean age 59±6 years), measuring galectin-3 and NTproBNP serum levels and specific echocardiographic parameters. Results: Galectin-3 was significantly higher in patients with COPD and elevated systolic pulmonary artery pressure than in healthy volunteers and discriminated better between patients with likely and possible pulmonary hypertension when compared to NT-proBNP. In multivariate analysis, the global model was better related to galectin-3 than to NT-proBNP levels (R²=0.61 vs. 0.31, p<0.001). Moreover, in contrast to NT-proBNP levels, correlations between galectin-3 levels and RV dysfunction, as assessed by the E/E' ratio and RV ejection fraction, persisted after adjustment for cardiovascular risk factors and COPD-induced inflammation. Conclusion: In patients with COPD-associated pulmonary hypertension presenting with acutely aggravated dyspnoea, galectin-3 levels are predictive of RV dysfunction and correlate better with RV dysfunction parameters compared to NT-proBNP.
Introduction
Heart failure is a disabling condition occurring in 1-2% of the adult population [1] and is associated with progressive cardiac remodeling and impaired diastolic and/or systolic ventricular function. Chronic obstructive pulmonary disease (COPD) is the most common aetiology of right ventricle (RV) remodeling, leading to chronic cor pulmonale, pulmonary hypertension (PH), and RV cardiac dysfunction, thus affecting patients' prognosis [2] . Due to the high prevalence of PH among hospital discharges for chronic respiratory diseases [3] , early recognition of highrisk patients is essential and biomarkers are increasingly being recognized to have great clinical value.
During the last decade, N-terminal B-type natriuretic peptide (NT-proBNP) has been the preferred biomarker for assessing the cardiac impairment. In patients with COPD, elevated NT-proBNP levels [4, 5] were shown to be related to disease progression, aggravated respiratory failure, and secondary PH [4, 6] . However, other factors which are not necessarily related to the underlying heart disease interfere with NT-proBNP levels such as pro-inflammatory states, hypoxia, or the activity of the sympathetic nervous system [7] .
Recently, galectin-3, a beta galactozide binding lectine overexpressed by macrophages during phagocyto-sis [8] , has emerged as a novel mediator of heart failure development and progression [9] . Galectin-3 was shown to induce cardiac fibroblast proliferation collagen storage associated with myocardial fibrosis [10, 11] and inflammation [12, 13] , leading to cardiac remodeling. In clinical studies, elevated galectin-3 levels were found in patients with heart failure, [8, [14] [15] [16] [17] [18] , particularly in patients with preserved left ventricle (LV) ejection fraction [14, 19] . The correlation between galectin-3 levels and RV dysfunction has been less thoroughly investigated [15] , but recent research has demonstrated that increased galectin-3 expression was correlated with epithelial proliferation and airway obstruction in patients with severe COPD [20] .
The aim of this prospective study was to assess the correlation between serum levels of galectin-3 and RV structural and functional parameters in patients with secondary PH due to COPD, as well as to establish and compare the diagnostic abilities of galectin-3 to NT-proBNP.
Material and methods
We conducted a prospective study on COPD patients presenting with acutely aggravated dyspnoea in the Department of Internal Medicine of the Cluj-Napoca Emergency Clinical County Hospital between October 2011 and November 2012. The study was performed in accordance with the principles set out in the Declaration of Helsinki and was approved by the University Ethics Committee on human research.
Patient selection
During the inclusion period 64 consecutive patients were considered as clinically eligible due to COPD and presentation for acutely aggravated dyspnoea. Main inclusion criteria to the study were: 1) systolic pulmonary artery pressure (sPAP) >36 mmHg at echocardiography; 2) sinus rhythm; 3) >55% left ventricular (LV) ejection fraction; 4) absence of other factors that might have induced PH (e.g. pulmonary embolism, significant valvular heart disease, known coronary heart disease, or left chamber cardiomyopathies); 5) absence of overt non-pulmonary inflammatory conditions or serious non-cardiac diseases (e.g., infection, neoplastic conditions, overt inflammatory disease) likely to influence NT-proBNP and galectin-3 levels. Out of 64 eligible patients, 40 patients were finally included (test group); 24 others were not selected due to various reasons: 16 patients were unlikely to have PH pending the echocardiographic examination; 3 had sustained arrhythmias; 3 had poor echocardiographic windows; 2 did not consent to participate. The test group was compared to 40 healthy volunteers, matched for age and sex, with normal ECG and no prior history of chronic diseases, without symptoms or treatment for chronic ailments, included between October 2012 and May 2013. Based on echocardiography sPAP values, the test group patients were divided in two subgroups with either possible (sPAP=37-50 mmHg) or likely (sPAP> 50 mmHg) PH [21] . All subjects were informed about the study protocol and invited to sign informed consents before being enrolled.
Study protocol
Each patient was submitted to a standard investigation protocol which included history, physical examination, chest radiography, and standard pulmonary function tests. The diagnosis and staging of COPD were established according to the criteria of the Global Initiative for Chronic Obstructive Lung Disease: forced expiratory volume in 1 second (FEV1)/forced vital capacity (FVC) ratio <70% [22] . Pulmonary function was assessed using a water-sealed Collin Survey II volume displacement spirometer. The New York Heart Association (NYHA) functional class and the exercise capacity using the 6 minute walk test according to American Thoracic Society guidelines [23] were evaluated at the baseline visit.
Echocardiography Standard echocardiography was performed using an Aloka ProSound 5500 (Aloka Co. Ltd, Tokyo, Japan) echocardiograph with wide-angle phased-array 2.5 MHz transducer, under simultaneous electrocardiogram monitoring. All data was digitally stored for off-line analysis. RV and LV systolic and diastolic function parameters were estimated as previously described [24, 25] . LV ejection fraction was calculated based on Simpson's modified single plane method using the apical 4-chamber view and values above 55% were considered normal [25] . Right atrium (RA) and RV dimensions were measured from the parasternal long axis and the apical 4 chambers views. The RV-RA systolic gradient was measured using the tricuspid regurgitant flow velocity. RA pressure was estimated based on the inferior vena cava diameter and inbreathe collapse, assessed from the subcostal view, and added to the RV-RA gradient to calculate sPAP. Functional assessment of the RV included conventional two dimensional and M-mode measurements, as well as tissue Doppler derived data. The following parameters were further measured: tricuspid annular plane systolic excursion (TAPSE), RV fractional area change (RVFAC), RV ejection fraction (RVEF), tissue Dopplerderived tricuspid lateral annular systolic velocity (S' velocity), and RV myocardial performance index (RVMPI). RVEF was calculated using Simpson's modified rule and an RVEF>50% was considered normal. RVFAC was derived from the formula (RV end-diastolic area -RV end-systolic area)/RV end-diastolic area and RVMPI was measured using tissue Doppler [24] . Diastolic RV function was assessed based on pulsed wave Doppler evaluation of the tricuspid flow and intraventricular pressure estimation by tissue Doppler. Early diastolic filling was assessed by measuring E wave velocity (cm/s), while A wave velocity (cm/s) was measured to estimate late diastolic filling. Early and late diastolic tissue Doppler velocities at the tricuspid annular plane (E' and A' velocity, cm/s), E/A and E/E' ratios at the tricuspid plane level, and tricuspid E wave deceleration time were also measured.
As previously described [24] , diastolic function was classified as normal -stage 0, or impaired, as follows: mild dysfunction -stage 1 or impaired relaxation pattern with E/A ratio<0.8, moderate dysfunction -stage 2 or pseudonormal pattern with E/A ratio in between 0.8-2.1 and E/E' ratio>6, and severe dysfunction -stage 3 or restrictive pattern with E/A ratio >2.2 and E wave deceleration time <120 ms. All these parameters were assessed by two expert echocardiographers in consensus, blinded to all biological tests and clinical data.
Galectin-3 and additional biochemical analysis
All biochemical markers were measured by the Department of Clinical Biochemistry. Two peripheral venous blood samples were collected from all patients on admission in tubes containing ethylene-diamine tetraacetic acid and centrifuged immediately; glucose, creatinine, and C-reactive protein levels were measured promptly from one plasma sample, using a Konelab 31 analyzer.The other plasma sample was frozen and stored at -70°C and analyzed for galectin-3 and NT-proBNP levels at the end of the patient inclusion period by a single investigator who was blinded to clinical data, including echocardiography results. Galectin-3 serum levels were measured using an enzyme-linked immunosorbent assay (Human Galectin-3 -Quantikine ELISA Kit, R&D Systems, lower mean limit of detection 0.016 ng/ mL, with no cross-reactivity with other galectins or collagens, plasma intra-assay variances for galectin-3 levels between 4.3%-3.5%, inter-assay variances between 5.8% and 6%). NT-proBNP levels were measured using automated enzyme immunoassay (Biomedica Gruppe, total imprecision between 4.4% and 3.8%). Renal function was evaluated based on the estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration formula [26] . Renal dysfunction was defined as eGFR < 60 mL/min/1.73m 2 .
Statistical analysis Data were assessed for normality using the Kolmogorov-Smirnov test for continuous variable distribution. Data with normal distribution were expressed as mean value ± standard deviation (SD), while data with nonnormal distribution were expressed as median value ± SD or interquartile ranges (IQRs) and log-transformed before further analysis. Relative frequencies for categorical variables were expressed as percentages. Variables with parametric distribution were analyzed by the Student test; variables with non-parametric distribution were compared between groups using the Chi square/ Fisher-test and the Mann-Whitney test. The KruskalWallis test was performed to assess and compare galectin-3 concentrations across the NYHA functional class. We conducted univariate analysis to evaluate variables likely to be related to galectin-3 and NT-proBNP levels. Multivariate analysis was further performed to establish the independent associations between galectin-3 and NTproBNP levels and functional echocardiography indices with adjustments for age, systolic blood pressure, and basic characteristics significantly related with biomarkers levels after univariate analysis (FEV1, eGFR and Creactive protein). Receiver-operator characteristic (ROC) curve analysis was performed to determine sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of galectin-3 and NT-proBNP for diagnosing RV dysfunction, with 95% confidence interval (CI). Cut-off values were established for the essential biomarkers, yielding significance levels and main reliability indices. P-values <0.05 were considered to be statistically significant. Statistical analysis was performed using MedCalc Software 12.1.1 (Mariakerke, Belgium).
Results

Baseline characteristics and clinical correlations with biomarker levels
Subject characteristics and baseline clinical, and laboratory data of the two groups are detailed in Table I and echocardiographic data are detailed in Table II. Galectin-3 and NT-pro BNP level distribution was non-normal. Accordingly, values were log-transformed and further analysed in subgroups depending on NYHA class, RVEF, diastolic function, and sPAP values. Baseline galectin-3 and NT-proBNP levels were significantly higher in COPD patients compared to healthy subjects (p<0.001 for the two biomarkers). In addition, both levels of galectin-3 and NT-proBNP increased significantly with aggravated NYHA class, the decline in RVEF and the severity of RV diastolic dysfunction (data not shown).
However, only galectin-3 levels were able to discriminate between patients with sPAP <50mmHg and patients with sPAP >50 mmHg, while differences in NT-proBNP levels between these two subgroups were non-significant. For a cut-off value of 14.4 ng/ml, galectin-3 showed 90.7% specificity and 73.8% sensitivity for distinguish-tionship between clinical and biochemical covariates and both galectin-3 and NT-proBNP levels (data not shown). Higher galectin-3 and NT-proBNP levels were positively correlated with current active smoking, elevated C-reactive protein levels, as well as with increased systolic blood pressure and FEV1 (p<0.001). No statistically significant correlations have been established between galectin-3 or NT-proBNP levels and age, gender, body surface area, or body mass index.
Correlations between galectin-3 or NT-proBNP levels and right chamber echocardiography parameters are presented in Table III . Significant correlations were found being patients with sPAP> 50 mmHg, with associated NPV and PPV of 87.5% and 79.2%, respectively. Despite better sensitivity -92.3% and NPV -95.1%, NT-proBNP performed poorly in terms of specificity -72.2%; and PPV -61.5% for identifying sPAP >50 mmHg in test group patients.
Correlation between Galectin-3, echocardiographic parameters, and other biomarker levels Significant correlation was found between log-transformed galectin-3 and NT-proBNP levels, and RV systolic and diastolic dysfunction parameters and sPAP ( fig  1) . Univariate analysis was performed to assess the rela- tween galectin-3 and NT-proBNP levels and right chamber dimension parameters (p<0.001), as well as RV systolic function indices, such as TAPSE, S' velocity, RVIMP, RVFAC and RVEF (p<0.001). Some RV diastolic function parameters, including tissue Doppler E' and A' peak velocities, as well as the E/E' ratio were also correlated to galectin-3 levels (p<0.001). RVEF and sPAP presented the strongest correlation to both biomarkers. Galectin-3 levels were found inversely correlated with LV ejection fraction (p=0.001) and positively correlated to left atrium (LA) volume index (p=0.001) and E/E' mitral ratio (p=0.001), but all these relations disappeared after adjusting to RVEF.
In multivariate analysis (Table IV) , galectin-3 was moderately correlated with the basic model including age, systolic blood pressure, and other characteristics linearly related to biomarkers levels such as active smoking, FEV1 and C-reactive protein. However, the relation with this model performed better with galectin-3 than with NTproBNP levels (R²=0.54, p<0.001 vs. R²=0.28, p=0.001). Furthermore, when either RVEF (R²=0.59, p<0.001) or E/E' ratio (R²=0.58, p<0.001) or both (R²=0.60, p<0.001) were added to the basic model, correlations with galectin-3 levels became even stronger, and still better than with NT-proBNP levels (R 2 = 0.28, p=0.001; R 2 =0.29, The results are expressed as mean (SD). LA -left atrium; LV -left ventricle; sPAP -systolic pulmonary artery pressure; RA -right atrium; RV -right ventricle; RVEF -RV ejection fraction; RVFAC -RV fractional area change; RVMPI -RV myocardial performance index; TAPSE -tricuspid annular plane systolic excursion.
p<0.001; and R 2 =0.30, p<0.00, respectively). Thus, galectin-3 levels were proved to be independent predictors of RV dysfunction after adjusting for others co-variables. The best correlation with galectin-3 was obtained when RVEF, E/E' ratio and sPAP were added to the basic model (R²=0.61, p<0.001). For the same model, correlations to NT-proBNP were only weak (R²=0.31, p<0.001). ROC curve analysis was used to test the ability of galectin-3 and NT-proBNP for identifying systolic dysfunction (RVEF <40%), with an AUC of 0.815 (95%CI: 0.712 to 0.893, p<0.0001) for galectin-3 and of 0.783 (95%CI: 0.677 to 0.868, p<0.0001) for NT-proBNP. Furthermore, to test the ability for identifying severe RV diastolic dysfunction, AUCs of galectin-3 and NT-proBNP were estimated to 0.964 (95%CI: 0.865 to 0.997, p<0.0001) and 0.954 (95%CI: 0.849 to 0.994, p<0.0001), respectively.
Discussions
The results of the current study support the initial hypothesis that high galectin-3 levels are associated with an increased risk for developing heart failure and highly predictive of RV dysfunction in patients with COPD-associated PH. Galectin-3 levels were found to be significantly correlated with RV diastolic dysfunction, impaired RV systolic function and higher sPAP levels, which is an element of novelty. Although earlier research confirmed the link between galectin-3 and LV dysfunction [27, 28] , studies testing the associations between galectin-3 levels and RV parameters were not previously available. As others [14, 15, 17, 19] , we have shown that galectin-3 may predict functional capacity, as galectin-3 levels, adjusted for RVEF, increased with advancing NYHA functional class and lower six minute walk test distances. These correlations were particularly obvious in the higher PH subgroup, which displayed the highest galectin-3 levels, the lowest RVEF and the shortest six minute walk test distances. Interestingly, NT-proBNP levels did not increase significantly in this subgroup, suggesting that galectin-3 is superior in terms of discriminating between patients with possible and likely PH.
Since previous studies have suggested that inflammation, elevated blood pressure, high body mass index, ac- LA -left atrium; LV -left ventricle; sPAP -systolic pulmonary artery pressure; RA -right atrium; RV -right ventricle; RVEF -RV ejection fraction; RVFAC -RV fractional area change; RVMPI -RV myocardial performance index; TAPSE -tricuspid annular plane systolic excursion. tive smoking, and impaired renal function were possible confounding factors for the correlation between galectin-3 and NT-proBNP levels, and LV function parameters [10, 19, 20, [29] [30] [31] [32] , we took into account all these parameters in multivariate analysis, as well as other variables which have shown to be linearly related to galectin-3 levels. Thus, unlike for NT-proBNP, correlations between galectin-3 levels and RV morphology and function parameters persisted after adjustment for these confounding factors. Univariate analysis was also used to test the correlation between galectin-3 and NT-proBNP. Initially, the correlation between the two biomarkers was strong, but did not persist after adjusting for RVEF or levels of diastolic RV dysfunction, which suggest that one of the two biomarkers may be superior in identifying RV dysfunction. By comparing AUCs (Figure 3) , we found that galectin-3 is non-inferior to NT-proBNP in the detection of RV systolic or diastolic dysfunction. RV dysfunction was identified with high sensitivity and specificity, although previous research has shown that these indices were considerably lower by comparison with NT-proBNP when attempting to assess the presence of LV dysfunction [30] . Importantly, LV ejection fraction was also found to be significantly reduced in test group patients by comparison with healthy volunteers and significantly correlated to higher galectin-3 values. However, this apparently confounding result can be justified by impaired LV filling, which is a common occurrence in COPD patients, as previously shown [33] [34] [35] . Many COPD patients exhibit tachycardia due to hypoxemia and associated medication [36] , leading to shorter diastole and, implicitly, to poorer filling which may further influence LV ejection fraction.
The main limitation of the current study is represented by the lack of heart catheterization which may have hindered the precise diagnosis and staging of PH. Furthermore, some RV-related structural and functional parameters are sometimes difficult to assess by echocardiography, a limitation which we tried to diminish by only choosing patients with very good acoustic views. Although RV evaluation by cardiac magnetic resonance imaging would have been more accurate, it was not feasible during the conduction of this study
Conclusions
Despite the mentioned encumbrances, several valid conclusions were drawn. Firstly, elevated galectin-3 levels are well correlated to clinical and echocardiographic indices of RV dysfunction in COPD patients with elevated sPAP presenting with acutely aggravated dyspnoea. Also, based on this data, it is reasonable to conclude that beyond the role of inflammation-induced COPD, in contrast to NT-proBNP levels, RV functional impairment and elevated pulmonary pressure can be considered as major determinants of elevated galectin-3 levels.
It is reasonable to assume that, although galectin-3 is as valuable as NT-proBNP in predicting cardiovascular outcomes in patients with heart failure due to LV dysfunction, it may provide additional benefits in COPD patients with RV failure presenting with acutely aggravated dyspnoea. Further extensive research focused on cardiovascular outcomes in COPD patients with RV dysfunction is required to test the diagnostic and prognostic abilities of galectin-3.
